Torrent Pharmaceuticals Limited announced that it is expanding its recall of Losartan potassium tablets because of the detection of trace amounts of N-nitrosodiethylamine, or NDEA, above the acceptable daily intake levels released recommended by the U.S. Food and Drug Administration. Torrent Pharmaceuticals recalled two lots of the tablets in December, but the recall has now widened to 10 lots. An unexpected impurity was found in an active pharmaceutical ingredient manufactured by Hetero Labs Limited. The Medication is used by patients to treat high blood pressure and diabetic kidney disease. Last week, 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP were recalled because of the presence of NDEA. Drugs involved in the recall are all part of a large class of drugs called angiotensin II receptor blockers, which work by blocking the effects of a hormone that narrows blood vessels.